Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of mRNA from splenic and hepatic CD8 T cell populations after resolved and during persistent AdV infection

ABSTRACT: RNAseq of mRNA from splenic and hepatic CD8 T cell populations after resolved and during persistent AdV infection

PROVIDER: PRJNA706019 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13833700_1.fastq.gz	Fastqsanger.gz
	SRR13833700_2.fastq.gz	Fastqsanger.gz
	SRR13833701_1.fastq.gz	Fastqsanger.gz
	SRR13833701_2.fastq.gz	Fastqsanger.gz
	SRR13833702_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

RNAseq of mRNA from splenic and hepatic CD8 T cell populations after resolved and during persistent AdV infection

Project description:We aimed at dissecting phenotype, functionality and regulation of antigen-specific hepatic and splenic CX3CR1-positive and hepatic CXCR6-positive CD8 T cells after resolved or during persistent viral infection of the liver.

2024-04-29 | GSE168096 | GEO

Comparison of Ildr2 knockdown by (Adv-shRNA) and Ildr2 knockout (Adv-Cre) in mouse liver

Project description:We observed that Ildr2 knockdown via adenovirally-delivered shRNA (Adv-Ildr2 shRNA) causes hepatic steatosis in mice. Acute, liver-specific Ildr2 knockout mice generated by infecting C57BL/6J mice segregating for a floxed allele of Ildr2 with adenoviral Cre recombinase (Adv-Cre) do not develop hepatic steatosis. However, administration of Adv-Ildr2 shRNA to Ildr2 knockout mice (Ildr2floxed; albumin-cre) did cause hepatic steatosis, indicating that the Adv-Ildr2 shRNA had apparent “off-target” effects on gene(s) other than Ildr2. To determine additional targets of Ildr2 shRNA that may regulate hepatic lipid metabolism, we performed RNA sequencing on liver samples from (1) Adv-Ildr2 shRNA knockdown mice, (2) Adv-lacZ shRNA control mice, and (3) Adv-Cre Ildr2 knockout mice. For the purposes of our study, we sought to identify genes downregulated by Adv-Ildr2 shRNA, but unchanged in Adv-lacZ shRNA control or Adv-Cre Ildr2 knockout mice. The hepatic steatosis observed in Adv-Ildr2 shRNA knockdown mice was likely due to shRNA targeting of other “off-target” genes. We propose that the genes candidates identified in this sequencing experiment may lead to identification of novel regulators of hepatic lipid metabolism.

2018-05-11 | GSE114289 | GEO

IL-27 production by splenic immune cells throughout persistent LCMV infection

Project description:IL-27 production by splenic immune cells throughout persistent LCMV infection

| PRJNA776720 | ENA

Compare the differences in gene expression of TAMs in mouse tumor tissues treated with AdV-Fe3O4@PACM and AdV-iCD47-Fe3O4@PACM.

Project description:Oncolytic adenoviruses (AdVs) represent a promising immunotherapeutic approach against cancer, yet their clinical translation is hindered by rapid systemic clearance, poor tumor accumulation, limited extravasation across the endothelial barrier, and an immunosuppressive tumor microenvironment. To overcome these challenges, we developed a biomimetic nanocomplex, AdV-iCD47-Fe₃O₄@PACM, consisting of an oncolytic adenovirus chemically conjugated with chemically modified CD47 siRNA and loaded with Fe₃O₄ nanoparticles, all encapsulated within a palmitoylated cancer cell membrane (PACM). Upon intravenous administration, the PACM coating enables immune evasion and prolonged circulation. Application of an external magnetic field promotes active tumor targeting via Fe₃O₄, while palmitic acid moieties transiently increase vascular permeability by downregulating tight junctions, facilitating nanocomplex extravasation into the tumor interstitium. Once inside tumor cells, the oncolytic AdV induces direct cytolysis, and the released chemically modified siRNA achieves sustained CD47 silencing, blocking the “don’t eat me” signal and enhancing macrophage-mediated phagocytosis. This dual mechanism—direct oncolysis combined with innate immune checkpoint blockade—elicits a robust antitumor immune response. Both in vitro and in vivo evaluations demonstrate that the AdV-iCD47-Fe₃O₄@PACM platform effectively overcomes key barriers of systemic delivery and immunosuppression, offering a promising strategy for enhanced cancer immunotherapy.

2026-04-24 | GSE328517 | GEO

Comparison of Ildr2 knockdown by (Adv-shRNA) and Ildr2 knockout (Adv-Cre) in mouse liver

Project description:Comparison of Ildr2 knockdown by (Adv-shRNA) and Ildr2 knockout (Adv-Cre) in mouse liver

| PRJNA470815 | ENA

Mouse thymic, splenic B cells and splenic DC immunopeptidome

Project description:C57BL/6 Mouse: I-Ab immunopeptidome presented by thymus, splenic B cells and splenic DCs. Human lymphoblastoid cells: HLA-DR immunopeptidome identified from different cell dilutions. Splenic B cells Files- B cells 1 (121616WTII), B cells 2 (072417MHCII-1), B cells 3(072417MHCII-2) Thymus Files-Thymus 1 (120116WTII), Thymus 2 (020617WT MHCII), Thymus 3 (061417MHCII WT-1), Thymus 4 (061417MHCII WT-2) Splenic DCs- DC1 (021517 Immature), DC2 (021517 Mature), DC3 (022018_BL6_Control), DC4 (022018_BL6_FLT3)

2021-03-10 | MSV000087031 | MassIVE

2875 Adv Tumor Proteomics

Project description:2875 Adv Tumor Proteomics. Synapt G2, HDMSE (global) DDA (phos).

2018-10-12 | MSV000083030 | MassIVE

Unmasking budgerigar splenic leukocyte populations with single cell transcriptomics

Project description:Budgerigar splenic leukocyte populations have not been examined yet. With single cell transcriptomics we aimed to identify the different immune subpopulations and compare the immune system of these psittacine birds with chickens.

2025-12-02 | GSE273701 | GEO

RNAseq of mRNA from hepatic CD8 T cell populations after low dose and during high dose AdV infection

Project description:RNAseq of mRNA from hepatic CD8 T cell populations after low dose and during high dose AdV infection

| PRJNA640663 | ENA

Persistent backtracking by RNA polymerase II

Project description:RNA polymerase II (pol II) can backtrack during transcription elongation, exposing the 3’ end of nascent RNA. Nascent RNA sequencing can approximate the location of backtracking events that are quickly resolved; however, the extent and genome wide distribution of more persistent backtracking is unknown. Consequently, we developed a novel method to directly sequence backtracked RNA. Our data shows that pol II slides backwards more than 20 nucleotides in human cells and can persist in this backtracked state. Persistent backtracking mainly occurs where pol II pauses near promoters and intron-exon junctions, and is enriched in genes involved in translation, replication, and development, where gene expression is inhibited if these events are unresolved. Histone genes are highly prone to persistent backtracking, where the accumulation and resolution of such events is required for timely expression during cell division. These results demonstrate that persistent backtracking has the potential to affect diverse gene expression programs.

2024-02-10 | GSE235830 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data